Compare LNG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | EW |
|---|---|---|
| Founded | 1983 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5B | 49.9B |
| IPO Year | 1996 | 1999 |
| Metric | LNG | EW |
|---|---|---|
| Price | $244.42 | $94.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $294.87 | $96.37 |
| AVG Volume (30 Days) | 2.1M | ★ 4.1M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 69.93 | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $19,976,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $16.48 | $13.39 |
| Revenue Next Year | $5.89 | $9.81 |
| P/E Ratio | ★ N/A | $142.91 |
| Revenue Growth | ★ 27.21 | 11.55 |
| 52 Week Low | $186.20 | $72.30 |
| 52 Week High | $300.94 | $94.47 |
| Indicator | LNG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 70.11 |
| Support Level | $220.29 | $82.02 |
| Resistance Level | $255.48 | N/A |
| Average True Range (ATR) | 7.30 | 2.37 |
| MACD | 1.95 | 0.51 |
| Stochastic Oscillator | 84.50 | 99.12 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.